Lanadelumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fully human immunoglobulin G1 (IgG1) monoclonal antibody against plasma kallikrein that can be used for the treatment of hereditary angioedema (HAE). Upon administration, lanadelumab targets and binds to plasma kallikrein, thereby inhibiting its proteolytic activity. This inhibits the cleavage of high-molecular-weight-kininogen (HMWK) into cleaved HMWK (cHMWK) and bradykinin. This in turn may prevent bradykinin-driven vasodilation, the resulting increase in vascular permeability, and the swelling and pain associated with HAE. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.

**Synonyms:** - DX-2930 - LANADELUMAB - Lanadelumab-flyo - SHP643 - TAK-743 - Takhzyro